More Lawsuits AGAIN

Discussion in 'Valeant Pharmaceuticals' started by Anonymous, Dec 18, 2014 at 11:05 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    COTCHETT, PITRE & McCARTHY, LLP (www.cpmlegal.com) today announced that a class action has been commenced in the United States District Court for the Central District of California on behalf of persons who sold Allergan, Inc. (AGN) common stock between February 25, 2014 and April 21, 2014 (the “Class Period”).

    If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from December 17, 2014. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Mark Molumphy of Cotchett, Pitre & McCarthy at (650) 697-6000. If you are a member of this class, you can view a copy of the complaint online at http://www.cpmlegal.com/cases-valeant-lawsuit.html. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

    The complaint charges defendants Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, AGMS Inc., Pershing Square Asset Management L.P., William A. Ackman, PS Management GP, LLC, and PS Fund 1, LLC (“Defendants”) with violations of Sections 14(e) and 20A of the Securities Exchange Act of 1934, as amended.

    Plaintiff alleges that Valeant unlawfully tipped Pershing Square about its plan to make a tender offer for Allergan, with Pershing Square then trading on such material, non-public information by buying an approximately 9.7% stake in Allergan during the Class Period without first disclosing Valeant's plan to pursue a tender offer to acquire Allergan at a significant premium.

    When Valeant first disclosed its desire to pursue an acquisition of Allergan to the stock market on April 22, 2014, Allergan's stock price soared, rising from a closing price the previous day of $141.88 to close at $163.51 on April 22, 2014 on huge volume of over 32 million shares – ten times Allergan's average daily trading volume during the Class Period.

    Plaintiff seeks to recover damages on behalf of all persons who sold Allergan stock between February 25, 2014 and April 21, 2014, inclusive. Plaintiff alleges that class members were damaged by selling their Allergan stock during the Class Period at prices that did not reflect Valeant's anticipated tender offer to acquire Allergan at a significant premium. The plaintiff is represented by Cotchett, Pitre & McCarthy, which specializes in representing investors and has extensive experience in prosecuting securities class actions.
     

  2. Anonymous

    Anonymous Guest

    To bad Valeant already used that money to prop up earnings last quarter. I'm still waiting to hear about what reserves they set aside to settle the lawsuits. So far no mention from top brass, just creative accounting touting the millions they earned from the Allergan takeover attempt on the insider trading (Its only insider trading if you look at what the judge said... Valeant won't admit it until the class action suit forces them to).
     
  3. Anonymous

    Anonymous Guest

    More today:


    Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors Who Sold Allergan, Inc. Common Stock Between February 25, 2014 and April 21, 2014


    Expect to see lots more, this will cost $$$$ millions!!!
     
  4. Anonymous

    Anonymous Guest

    And they just keep on comin


    AGN SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 16, 2015 -- AGN
     
  5. Anonymous

    Anonymous Guest

    The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who sold the common stock of Allergan Inc. (“Allergan” or the “Company”) (AGN) between February 25, 2014 and April 21, 2014, inclusive (the “Class Period”).

    If you sold Allergan common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than February 17, 2015. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

    Allergan investors who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

    Background on the Allergan Securities Class Litigation

    Allergan is a multi-specialty health care company headquartered in Irvine, California. The action charges Valeant Pharmaceuticals International, Inc. (“Valeant”), Pershing Square Capital Management, L.P. (“Pershing Square”), the founder and Chief Executive Officer of Pershing Square, William A. Ackman, and related entities, with violations of the Securities Exchange Act of 1934.
     
  6. Anonymous

    Anonymous Guest

    How's Pearson gona fund these?
     
  7. Anonymous

    Anonymous Guest

    Probably wIll get dropped. Won't have to pay.
     
  8. Anonymous

    Anonymous Guest

    Hey Mikey, you got wayyy too many lawsuits on your hand, thanks mgt troll for that
     
  9. Anonymous

    Anonymous Guest

    LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 17, 2015